Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 7/20 | 0.44 |
| ▸ | THRA | P10827 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 10/20 | 0.39 |
| ▸ | RARA | P10276 | 2/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19855022 | 0.96 | THRB (0.43) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19855484 | 0.92 | THRB (0.43) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19855938 | 0.92 | THRB (0.45) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL20370521 | 0.91 | THRB (0.44) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19854475 | 0.91 | THRB (0.44) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL20370446 | 0.91 | THRB (0.44) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19855942 | 0.91 | THRB (0.50) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19854453 | 0.87 | RARB (0.44) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL20370615 | 0.87 | THRB (0.50) | THRBTHRAMEN1KMT2ARARB | |
| SCHEMBL19855480 | 0.85 | THRB (0.40) | THRBTHRAMEN1KMT2ARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180195005-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, MBD2, PAXBP1 | THRB 3939/4885THRA 3929/4885MEN1 73/4885 |
| US-10662379-B2 | Polymerizable polar compound, liquid crystal composition and liquid crystal display device | SP1, MBD2, PAXBP1 | THRB 3939/4885THRA 3929/4885MEN1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.